Compare Novartis AG (NVS) vs UiPath Inc (PATH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs UiPath Inc — how do they compare? Novartis AG trades at $153.88 (market cap $290.25B), while UiPath Inc trades at $12.03 (market cap $6.30B). The key difference: Novartis AG is far larger — about 46.1× UiPath Inc's market cap, and Novartis AG pays a 3.17% dividend while UiPath Inc pays none. Which is the better fit depends on your goals.
| NVS | PATH | |
|---|---|---|
Market Cap | $290.25B | $6.30B |
Sector | Health | Technology |
52-Week High | $168.62 | $19.29 |
52-Week Low | $113.50 | $9.38 |
Enterprise Value | $330.27B | $5.08B |
Dividend Yield | 3.17% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About UiPath Inc
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →
